research use only

Lonidamine Carbohydrate Metabolism modulator

Name: Lonidamine
Brand: Selleck Chemicals
SKU: S2610
Availability: InStock
Rating: 5 (15 reviews)

Cat.No.S2610

Lonidamine is an orally administered small molecule hexokinase inactivator.

Chemical Structure

Molecular Weight: 321.16

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.90%

99.90

Related Targets	P450 (e.g. CYP17) Dehydrogenase PDE phosphatase PPAR HSP Vitamin Transferase Mitochondrial Metabolism Drug Metabolite Casein Kinase Serine/threonin kinase Lipoxygenase LPL Receptor Phospholipase (e.g. PLA) Retinoid Receptor DPP ACE Peroxidases Amino Acids and Derivatives Fatty Acid Synthase Glucokinase FXR HMG-CoA Reductase Carbonic Anhydrase Lipase Decarboxylase DHFR IDO/TDO Hydroxylase
Related Products	2-Deoxy-D-glucose (2-DG) Bromopyruvic acid (3-BP) LY2608204 1-Deoxynojirimycin Dorzagliatin 4',7-Dimethoxy-5-Hydroxyflavone Voglibose BI-9787 Hexokinase 1 Antibody [F18A5] Eleutherol Kaempferol-3-O-neohesperidoside Nodakenetin DLST Antibody [K3H24] AZD1656 N-Caffeoyl O-methyltyramine GALT Antibody [C15E2] GAA Antibody [H21L6] PCK1 Antibody [P16P6] FBPase-1 inhibitor-1 Butyl isobutyl phthalate Andrographis Herba Extract GFPT2 Antibody [C1C22] AM2394 M6PR (cation dependent) Antibody [J4M13] PFKM + PFKL Antibody [K8F12] Viburnum Dilatatum Extract Hexokinase II Antibody [F23A5] Ketohexokinase inhibitor 1 WAY-297848 FBP1 Antibody [A7L2]

Chemical Information, Storage & Stability

Molecular Weight	321.16	Formula	C₁₅H₁₀Cl₂N₂O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	50264-69-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	AF-1890, Diclondazolic Acid, DICA			Smiles	C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O

Solubility

In vitro
Batch:

DMSO : 64 mg/mL (199.27 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.000mg/ml (9.34mM)	Taking the 1 mL working solution as an example, add 50 μL of 60 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.500mg/ml (7.78mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	hexokinase ^[1]
In vitro	Lonidamine reduces the oxygen consumption in both normal and neoplastic cells, while it increases the aerobic glycolysis of normal cells but inhibited that of tumor cells. ^[1] This compound induces the permeabilization of ANT proteoliposomes in a cell-free system, yet has no effect on protein-free liposomes. It adds to synthetic planar lipid bilayers containing ANT, eliciting ANT channel activities with clearly distinct conductance levels. ^[2] It provokes a disruption of the mitochondrial transmembrane potential which precedes signs of nuclear apoptosis and cytolysis. This chemical causes the dissipation of the mitochondrial inner transmembrane potential and the release of apoptogenic factors capable of inducing nuclear apoptosis in vitro. ^[3] This compound (50 mg/mL) induces apoptosis in resistant cells (MCF-7 ADR(r) human breast cancer cell line, and LB9 glioblastoma multiform cell line), as demonstrated by sub-G1 peaks in DNA content histograms, condensation of nuclear chromatin, and internucleosomal DNA fragmentation. ^[4] It has a stronger effect on glioblastoma cell proliferation and metabolism in vitro than did either agent used alone. ^[5]
In vivo	Lonidamine (160 mg/kg) in combination is significantly more effective in reducing glioblastoma tumor growth than either drug alone in mice, this tumor growth retardation is maintained as long as treatment is given. ^[5]
References	[1] https://pubmed.ncbi.nlm.nih.gov/6937706/ [2] https://pubmed.ncbi.nlm.nih.gov/11753636/ [3] https://pubmed.ncbi.nlm.nih.gov/10353597/ [4] https://pubmed.ncbi.nlm.nih.gov/8787680/ [5] https://pubmed.ncbi.nlm.nih.gov/9747871/ [6] https://pubmed.ncbi.nlm.nih.gov/21220050/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02758860	Completed	Colonic Diverticula	University of Roma La Sapienza	June 2016	--
NCT00182078	Completed	Posttraumatic Stress Disorder\|Depression	Massachusetts General Hospital	November 2002	Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please test an in vivo formulation for this compound? Can it be administrated via i.p. injection?

Answer:
The suggested IP formula of S2610 is 5%DMSO+30%PEG300+5%Tween-80+ddH2O.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):